Effect of compound Kushen injection combined with pemetrexed + cisplatin program on quality of life, immune function and tumor markers in patients with advanced NSCLC

Abstract

Objective To observe the effect of Compound Kushen injection combined with AP regimen (pemetrexed + cisplatin) on quality of life, immune function and tumor markers in patients with advanced non-small cell lung cancer (NSCLC). Methods A retrospective study was performed on 82 cases of advanced NSCLS patients who were admitted from May 2015 to May 2017.Patients were randomly divided into the combined treatment group and AP group, with 41 cases in each group.There were 41 cases in AP group, including 25 males and 16 females.Aged (48.1±4.3) years old, ranging from 34 to 57 years old.There were 41 cases in the combined treatment group, including 23 males and 18 females.Aged (48.6±4.6) years old, ranging from 31 to 59 years old.Patients in the AP group were treated with pemetrexed + cisplatin, and patients in the combined treatment group were treated with compound Kushen injection on the basis of the AP group.The therapeutic effect, quality of life, immune function indexes, tumor markers and adverse reactions of the two groups were observed and compared. Results After treatment, the objective remission rate[48.8% (20/41)]and clinical benefit rate[87.8% (36/41)] in the combined treatment group were significantly higher than those in the AP group[24.4% (10/41) and 70.7% (29/41)], with statistically significant differences (P 0.05). After treatment, the above quality of life (QOL) scores were significantly increased in both groups, and the combined treatment group was significantly higher than the AP group, with statistically significant differences (P 0.05). After treatment, the above indicators were significantly increased in both groups, and the combined treatment group was significantly higher than the AP group, with statistically significant differences (P 0.05). After treatment, the above indicators were significantly reduced in both groups, and the combined treatment group was significantly lower than the AP group, with statistically significant differences (P<0.05). During the treatment period, liver function injury, cardiovascular toxicity, bone marrow suppression, gastrointestinal reaction, neurotoxicity and renal function injury in the combined treatment group were significantly lower than those in the AP group, with statistically significant differences (P<0.05). Conclusion The method of compound Kushen injection combined with AP program on patients with advance NSCLC can improve the clinical efficacy, worth to be further studied. Key words: Compound Kushen injection; AP program; Advanced non small cell lung cancer